Micafungina Hikma

Micafungin, the active ingredient in Micafungina Hikma, is an echinocandin presented as an intravenous formulation for infusion use. It treats invasive candidiasis, esophageal candidiasis, and is employed for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungina Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution and timely delivery.

Micafungin is an echinocandin antifungal that inhibits fungal cell wall synthesis and is indicated for the following conditions: - Invasive candidiasis: treatment of candidemia and deep‑tissue Candida infections, including organ involvement, in immunocompromised patients. - Esophageal candidiasis: eradication of Candida infection of the esophagus, relieving dysphagia and pain. - Prophylaxis of Candida infections in hematopoietic stem cell transplantation: prevention of invasive Candida disease in transplant recipients during the neutropenic phase.

Micafungin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fever - Nausea - Vomiting - Elevated liver enzymes (ALT, AST) - Headache

Serious or Rare Side Effects: - Severe hepatic failure or jaundice - Anaphylactic or severe hypersensitivity reactions - Acute renal impairment - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Prior to initiating micafungin therapy, clinicians should consider several safety precautions to minimize risk. - Renal function: assess baseline kidney function and monitor during treatment. - Hepatic function: evaluate liver enzymes before use and periodically thereafter. - Concomitant antifungal therapy: avoid overlapping use with other echinocandins to prevent additive toxicity. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Monitoring: observe for infusion‑related reactions and signs of hepatic or renal injury. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, requiring attention to avoid altered drug exposure or increased toxicity.

Major Interactions (Avoid): - Cyclosporine, tacrolimus, sirolimus: co‑administration markedly increases their blood concentrations, risking nephrotoxicity. - Concurrent use with other echinocandins (caspofungin, anidulafungin): may lead to additive toxicity without added benefit.

Moderate Interactions (Monitor Closely): - Rifampin or other strong enzyme inducers: may reduce micafungin plasma levels, potentially decreasing efficacy. - Azole antifungals (fluconazole, voriconazole): combined use can increase hepatic enzyme elevations. - Warfarin: micafungin may potentiate anticoagulant effect, requiring INR monitoring. - Statins (e.g., simvastatin): monitor for possible increased muscle toxicity.